Kidney-pancreas transplantation: Single-center experience at a University Hospital in Turkey


Yakupoğlu Y. K., Dinckan A., Gurkan A., Tuncer M., Erdogan O., Altunbas H., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, sa.7, ss.3205-3208, 2005 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.transproceed.2005.07.035
  • Dergi Adı: TRANSPLANTATION PROCEEDINGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3205-3208
  • Ondokuz Mayıs Üniversitesi Adresli: Hayır

Özet

Introduction. One treatment option for patients with type 1 diabetes mellitus with end-stage nephropathy is combined pancreas-kidney transplantation, which can be performed either simultaneously (SPK) or following kidney transplantation (PAK). Patients and Methods. Between February 2003 and November 2004, 14 patients, including 10 males and 4 females of overall mean age of 31.3 +/- 6.1 years (range, 23-44 years), presented with end-stage renal disease secondary to type 1 diabetes mellitus. Five patients (35.7%) received SPK; 7 patients (50%) received PAK; and 2 patients (14.3%) received simultaneous pancreas and living-related kidney (SPLK) transplantations. Results. Two among 14 pancreas grafts were lost in the early postoperative period secondary to venous thrombosis despite anticoagulation including I with poor portal drainage. Insulin therapy was reinitiated in 1 patient after a second rejection episode in the seventh postoperative month. By the ninth median follow-up month (range, 1-21 months), all kidney grafts were functioning. Conclusion. Our single-center short-term experience with 14 consecutive kidney-pancreas transplantations suggests that while the pancreas transplant is effective and safe to reestablish normoglycemia, this transplant creates additional surgical and immunosuppressive stresses on the patient.